Denver, CO 5/5/2008 8:17:49 AM
LegalView Announces the Arrival of A Breakthrough Scientific Study Allowing Insight Into the Development and Progression of Mesothelioma Cancer
Denver, CO - LegalView.com, the best resource for everything legal on the Web, recently announced breakthrough scientific research on the development and progression of human malignant mesothelioma cancer, which was published in the Cell Press in March. The new study, led by Dr. Anton Berns of The Netherlands Cancer Institute, uncovered a model system that allows researchers to further study the molecular mechanisms underlying malignant mesothelioma.
Mesothelioma is a fatal type of cancer that is caused through inhalation of asbestos fibers and dust, which slowly develops cancerous cells on the lining of the lungs and chest cavity. Individuals who often worked in mining vermiculite, the main mineral asbestos is derived from, or employees that transported asbestos have been highly affected, however, anyone who is exposed to even the smallest amounts of asbestos fibers are at risk for developing this condition. Asbestos was often used as installation on buildings from universities and elementary schools to hospitals and office buildings.
Today, the Environmental Protection Agency (EPA) regulates the cleanup of asbestos-contaminated buildings and individuals must comply with their regulations. Individuals who feel they may have been exposed to asbestos fibers are advised to speak with a medical professional immediately. Additionally, speaking with an experienced mesothelioma lawyer on the potential for developing a mesothelioma lawsuit, could result in monetary compensation providing a victim with relief from the hospital bills associated with this illness.
For more information on locating a mesothelioma attorney or learning more about treatments, jury verdicts and mesothelioma news, visit http://mesothelioma.legalview.com/. Also, LegalView offers other useful information portals with issues such as the controversy over Avandia, traumatic brain injury (TBI), and its recently updated Baxter Heparin portal with news of the ongoing investigation.
Avandia is a type 2 diabetes prescription medication from manufacturers GlaxoSmithKline, which has continually been linked to serious side effects including an increased risk of heart disease among patients as well as an elevated chance of developing early onset osteoporosis. The drug continues to be marketed even as these risks are being studied. Those who have taken Avandia should speak with a pharmaceutical law firm on developing an Avandia lawsuit.
LegalView's TBI practice area provides a wealth of information for victims of this condition, which affects millions of Americans each year. On the TBI practice area, use the attorney locator to find a lawyer in your area and receive a counsel on any possible brain injury lawsuit. Also, use the portal to look up the latest TBI news, jury verdicts and treatments.
Use the Baxter Heparin practice area to get the latest updates on the ongoing United States and China Heparin contamination controversy. Heparin, manufactured by Baxter International, is a blood-thinner used during surgical procedures including heart surgery. However, a batch of Heparin that was imported from China was reportedly contaminated causing a mass allergic reaction and nearly 90 deaths among patients who were administered the drug. As of now, both countries are placing blame for the contamination on each other. Follow the latest on the Heparin recall through the LegalView portal.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.
